Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD hydrocortisone after trauma trial
NL-OMON60332Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Hydrocortisone with Placebo (2 arms). Primary endpoint: PTSD symptom severity at 3 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
hydrocortisone
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NL-OMON60332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60332.